Alloy Therapeutics Inc., a biotechnology firm focused on broadening access to drug discovery technologies, has acquired Spannerwerks LLC, a Seattle-based consultancy that advises biopharmaceutical companies on product development and commercialization.

Under the terms of the deal, Spannerwerks will operate as a wholly owned subsidiary of Alloy and retain its name. Dara Lockert, Spannerwerks’ chief executive, will join Alloy full-time and continue to lead the team as part of the company’s executive leadership.

The acquisition signals Alloy’s strategic move beyond its core discovery platforms into drug development, aiming to support partners through key inflection points in the R&D lifecycle.

“Alloy has seen how critical it is for biotech innovators to access the right expertise at the right time,” said Errik Anderson, CEO and founder of Alloy Therapeutics. “By combining Alloy’s discovery platforms with Spannerwerks’ preclinical and clinical development capabilities, we’re giving our partners more flexibility, speed, and expert support to move their programs from idea to patients.”

Founded in 2015, Spannerwerks has established itself as a trusted partner for pharmaceutical and biotech firms, offering services from candidate selection through early clinical development. Its expertise spans integrated program management, toxicology, chemistry, manufacturing and controls (CMC), regulatory affairs, quality assurance, and clinical operations. The firm supports a range of therapeutic modalities, including small molecules, antibody-drug conjugates (ADCs), cell and gene therapies, and monoclonal and bispecific antibodies.

“Joining the Alloy ecosystem allows us to amplify what we do best: helping emerging biotechs navigate the complex and ever evolving path to the clinic,” Lockert said. “We’re excited to bring our team and expertise to a broader set of partners where we can deliver even more value to innovators who are working to bring transformative new medicines to patients.”

The acquisition also marks Alloy’s expansion into the Pacific Northwest, enhancing its global footprint and access to regional drug development talent. The company said the move reinforces its commitment to supporting partners from discovery through development while maintaining cost efficiency.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.